Shanghai Henlius Biotech and Organon (OGN) announced that the FDA has approved the biologics license application for Poherdy 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to Perjeta, for all indications of the reference product. Poherdy is the first and only approved pertuzumab biosimilar in the U.S.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: